Broadening and Narrowing Claims Post Issuance

There is some amount of tension between the Federal Circuit’s 2012 en banc decision in Marine Polymer Tech. v. HemCon (Fed. Cir. 2012) and the court’s recent finding in ArcelorMittal v. AK Steel (Fed. Cir. 2015). Both cases involved post-issuance proceedings where a claim’s scope had changed even though the claim itself had not been amended.

The underlying issue in Marine Polymer was whether a would-be infringer could claim have intervening rights under 35 U.S.C. §§ 252 and 307(b) if the scope of an non-amended claim was substantially changed during a reexamination.  The en banc Federal Circuit held that the a claim whose scope is narrowed-by-argument during a reexamination did not impact statutory intervening rights because the language of 307(b) focused the intervening rights only on a “amended or new claim.”  Because the claim was not actually amended, the law was not triggered.

In ArcelorMittal, we had a similar framework – in reissue the patentee expanded the scope of its non-amended independent claim based upon an a change to a dependent claim.  In its decision, the Federal Circuit found that the changed scope should be seen as a broadening of the original claim — triggering the prohibition against a broadened reissue (more than two years after the original patent issuance).

The difference between these two cases seems to primarily stem from the statutory language — the reissue statute and broadening doctrine seemingly do not require an “amendment” in order to be triggered while the intervening rights statute does. (I should note that this distinction is on somewhat shaky grounds).

The new inter partes review statute appears to closely follow that of the reexamination statute — indicating that intervening rights will stem from an “amended or new claim.”  The statute also provides that amendments “may not enlarge the scope of the claims of the patent.” 35 U.S.C. § 316.  The one question left unclear is the impact of broadening-through-claim-construction during the inter partes review.

Federal Circuit: 271(a) Does Not Include Joint Tortfeasor Liability

by Dennis Crouch

Akamai v. Limelight (Fed. Cir. 2015) (On remand from the Supreme Court)

On remand from the Supreme Court, a divided Federal Circuit has rejected calls to expand the scope of direct infringement to include a wider allowance for joint-tortfeasors when parties collectively practice all of the elements of a claimed invention. Rather, according to the majority opinion authored by Judge Linn, “the statutory framework of 35 U.S.C. § 271 does not admit to the sweeping notions of common-law tort liability argued in this case.”

Thus, the law remains that a party will not be liable for practicing several steps in a patented method and knowingly encouraging or instructing others to perform the remaining steps.  Here, the court distinguishes other situations such as a principal-agent relationship or a contractual arrangement where principal liability exist based upon the actions of the agent.  The court also notes that it may – in the future – expand direct liability to include “joint enterprise liability” but that “this case is not the appropriate vehicle.”

Writing in dissent, Judge Moore argues that the majority opinion “divorces patent law from mainstream legal principles by refusing to accept that § 271(a) includes joint tortfeasor liability. The majority’s rule creates a gaping hole in what for centuries has been recognized as an actionable form of infringement.”

Read the opinion here: http://www.cafc.uscourts.gov/images/stories/opinions-orders/9-1372.Opinion.5-11-2015.1.PDF

Emerging Trends Post-Octane Fitness

Guest Post by Hannah Jiam.  Ms. Jiam is now a 3L at UC Berkeley School of Law and research assistant with Professor Colleen Chien.  The full article related to this post is forthcoming in the Berkeley Technology Law Journal and is available here.

It has been a year since the Supreme Court’s decision in Octane Fitness[1] and Highmark[2], and fee-shifting continues to be a popular issue in patent reform. Testimony presented to the House Judiciary Committee on February 12, 2015 discussed the percentage of attorneys’ fees awards before and after Octane. This month, the House Judiciary Committee discussed the fee-shifting provision from the Innovation Act.[3] Congressman Bob Goodlatte, the Chairman of the Judiciary Committee, explained how the bill would “address the issues that businesses of all sizes and industries face from patent troll-type behavior.”[4] Director Michelle Lee of the PTO supported the fee-shifting provisions in the Innovation Act, saying that the “fault based fee-shifting will raise the costs for those who engage in abusive actions.” There have been several articles and papers discussing the impact of Octane Fitness, but none of them provide an in-depth analysis of the district court holdings and the emerging trends post-Octane. I would like to contribute my own research and empirical analysis on the issue.[5]

In the ten months following the Supreme court’s holding in Octane, there has been a significant increase in the number of motions made for attorneys’ fees under § 285, as well as the number of attorneys’ fees award to prevailing parties.[6] From April 29, 2014 to March 1, 2015, district courts awarded fees in twenty-seven out of sixty-three cases. This rate, approximately 43%, is at least two times greater than the fee-shifting award rate in previous years.[7] In fact, in the 12 months preceding Octane, only 13% of § 285 motions were granted.[8]

I sorted the § 285 motions granted and denied by district, and reproduced them in the graph below.

Figure 1 – § 285 Motions Granted/Denied by DistrictFig1 

Although there is not enough data at the moment to make any conclusive determinations, an initial analysis shows that there are certain districts with a higher proportion of cases in which attorneys’ fees were granted than cases where they were not. N.D. Cal. has the greatest total number of § 285 motions granted while D. Del. has the greatest total number of § 285 motions denied. For districts that have decided on four or more § 285 motions, S.D.N.Y. has the highest proportion of § 285 motions granted and D. Del. has the lowest proportion of § 285 motions granted. The majority of the § 285 motions appear to be concentrated in a small number of districts.

I also examined the percentage of § 285 motions granted over time from April 29, 2014 to March 1, 2015.

Figure 2 – Proportion of § 285 Motions Granted Over Time Post-Octane Fitness Fig2

The variation in the rates between each month could have been a result of any number of variables (such as a district court judge’s availability, the load of a district court’s docket, etc.), but the percentage of § 285 motions granted each month has always been above the 20% yearly average in 2002 and 2011, and well above the 13% award rate in the 12 months preceding Octane.

I created a histogram of the award amounts in cases where the § 285 motions have been granted. Most of the cases have not yet determined the amount of attorneys’ fees to be awarded to the prevailing party, but the majority of § 285 awards thus far have ranged from $200,000 to $300,000.

Figure 3 – Histogram of § 285 Fees AwardedFig3

Most courts have specifically limited the attorneys’ fees to the litigation misconduct and apportioned the fees to the “exceptional” behavior. This may explain why most of the fees are around $200,000 to $300,000.

Although the Supreme Court stated that the Federal Circuit’s standard was too stringent and inflexible, the Court did not define the standard for an “exceptional” case.[9] District courts now know that an “exceptional” case is not limited to circumstances where there has been “material inappropriate conduct,” or where the litigation is both “brought in subjective bad faith” and is “objectively baseless,” but have little guidance on the actual meaning of “exceptional.”[10] The meaning of “exceptional” continues to vary from case to case, but the Supreme Court’s decision reinforces a district court’s ability to use its discretion when deciding whether or not to award attorneys’ fees in “exceptional” cases.

Because the meaning of “exceptional” is still ambiguous and discretion may lead to forum shopping in district where fee awards are more or less likely under § 285, the “exceptional” case standard could benefit from further explanation. Unfortunately, the Federal Circuit’s ability to review a determination of “exceptionality” is limited by the Highmark decision, where the Supreme Court stated that a § 285 decision was a “matter of discretion” and that the exceptional-case determination should be reviewed only for abuse of discretion.[11] Any steps towards further patent reform would be most effective through legislation – Congress can clarify the fee-shifting provision or decide whether or not it wants to maintain an “exceptional” standard under § 285. Furthermore, the Supreme Court’s interpretation of an “exceptional” case places a strong emphasis on the discretion of the district courts despite the removal of the “discretion” element in the 1952 Act. If Congress wants to elucidate or maintain the Supreme Court’s reintroduction of discretion, it should not wait for litigation.

= = = = =

[1] Octane Fitness, LLC v. ICON Health & Fitness, Inc., 134 S. Ct. 1749 (2014).

[2] Highmark Inc. v. Allcare Health Mgmt. Sys., 134 S. Ct. 1744, 1747 (2014)

[3] Gene Quinn, House Judiciary Committee Questions PTO Director Lee on Innovation Act, IP Watchdog (Apr. 14, 2015), http://www.ipwatchdog.com/2015/04/14/judiciary-committee-director-lee-on-innovation-act/id=56813.

[4] Hearing: H.R. 9, The “Innovation Act”, United States House of Representatives Judiciary Committee (Apr. 14, 2015, 2:00 PM), http://judiciary.house.gov/index.cfm/hearings?ID=E71D6951-38DA-42D8-9485-8EC6CE929977.

[5] The entire paper can be read at: http://papers.ssrn.com/sol3/papers.cfm?abstract_id=2597195

[6] The following numbers were determined using LexisNexis and Westlaw to consolidate all cases from April 29, 2014 to March 1, 2015 involving a 35 U.S.C. § 285 motion. The cases retrieved were checked against a list on the blog Patently-O.com that consolidated several fee-shifting motions post-Octane. The analysis considered factors such as whether fees were awarded, the district, the court’s reasoning, and the award amount. Other analyses of § 285 motion decisions post-Octane have produced similar grant rates.

[7] In 2002, the attorneys’ fees were awarded only 10 times out of 50 total cases, and in 2011, only 20 times out of 86 cases. Colleen V. Chien, Reforming Software Patents, 50 HOU L. REV. 323, 380 n.355 (2012) (“Based on a search in Westlaw, in 2011, approximately twenty awards were made [on the basis of the exceptional cases rule of 35 U.S.C. § 285], and in 2002, ten awards were made. They were sought in eighty-six and fifty cases[, respectively].”)

[8] A Comparison of Pre Octane and Post Octane District Court Decisions on Motions for Attorneys’ Fees Under Section 285, available at http://ipwatchdog.com/materials/FCBA-Fee-Shifting-Paper.pdf.

[9] Octane Fitness, 134 S. Ct. at 1755.

[10] Brooks Furniture Mfg., Inc. v. Dutailier Int’l, Inc., 393 F.3d 1378, 1381 (Fed. Cir. 2005).

[11] Octane Fitness, 134 S. Ct. at 1749. (citing Highmark Inc. v. Allcare Health Mgmt. Sys., 134 S. Ct. 1744, 1747 (2014)).

Federal Circuit Finds Scope of Non-Amended Reissue Claims Improperly Broadened

by Dennis Crouch

ArcelorMittal v. AK Steel (Fed. Cir. 2015)

This case provides an important discussion of the “law of the case” doctrine and “mandate rule” as they apply to ongoing parallel patent-office administrative proceedings and in-court infringement proceedings. In particular, the appellate panel holds that the district court is bound by a prior Fed.Cir. claim construction in the same case – despite intervening decisions by the USPTO that the Fed.Cir. construction was too narrow.

The case is also important because of its finding that a claim whose scope is expanded during reissue based upon prosecution history (rather than amendment) will be seen as broadened – and thus may be invalid if the broadening misses the two-year deadline.

= = = = =

Here, the patentee (ArcelorMittal) lost its first round of infringement litigation based upon a narrow claim construction of the claimed steel sheet having a “very high mechanical resistance.”  Meanwhile, the patentee filed a reissue application with the USPTO that added a set of new dependent claims, including one that would seemingly expand the scope of the previously defined term.  In particular, the Federal Circuit originally ruled that the “very high mechanical resistance” is defined as having a resistance >1500 MPa, but the reissue application added a new dependent claim stating that the resistance is “in excess of 1000 MPa.”  That amendment seems to have implicitly increased the scope of claim 1 without actually amending any of the language in claim 1.  As the court writes:

The only relevant change is the addition of a dependent claim which has the practical effect of expanding the scope of claim 1 to cover claim scope expressly rejected by a previous claim construction ruling.

With the original litigation was still pending in district court, the patentee added the Reissued patent to the infringement complaint.  Siding with the defendant, the district court found that the broadened scope was improper because the Reissue application had been filed more than two years after the original patent issuance. On appeal, the Federal Circuit has affirmed, finding that – at least for this case – that the reissue claims are invalid. Here is the court’s logic:

The law-of-the-case doctrine “posits that when a court decides upon a rule of law, that decision should continue to govern the same issues in subsequent stages in the same case.” Banks v. U.S., 741 F.3d 1268, 1276 (Fed. Cir. 2014) (‘an inferior court has no power or authority to deviate from the mandate issued by an appellate court.’). Under the mandate rule and the broader law-of-the-case doctrine, a court may only deviate from a decision in a prior appeal if “extraordinary circumstances” exist. . . .

The successful prosecution of the [reissue] patent is not “new evidence” sufficient to trigger the extraordinary circumstances exception to the mandate rule and the law-of-the-case doctrine. Permitting a reissue patent to disturb a previous claim construction of the original claims would turn the [broadening] analysis under 35 U.S.C. § 251 on its head. . . . If the reissue claim itself could be used to redefine the scope of the original claim, this comparison would be meaningless.

Thus, the court found that the proper analysis for broadening reissue is whether the scope of claims in the reissued patent (as construed now) are broader than those same claims as found in the original patent (as previously construed).  I should note that the court did not particularly address the fact that the broadened claim was not amended. However, this practical approach to scope is in line with the Court’s prior decision in Marine Polymer Tech. v. Hemcon, Inc. (Fed. Cir. 2011) that created intervening rights (i.e., no past infringement) based upon a narrowed construction during reexamination.  [Update] Of course, that decision was reversed by the court sitting en banc.

= = = = =

The law-of-the-case doctrine was not necessary here because the court also found that, when considering whether scope was improperly broadenend, the reissue’s prosecution cannot impact the scope of the original claims.

Going forward, there will be substantial pressure on law-of-the-case doctrine; the mandate rule; and the final judgment rule in managing the new multi-venue reality of patent enforcement/challenge.

An important question not addressed here for reissue applications is whether the PTO erred allowing the reissue claims to issue in their non-amended but broadened form? Was the PTO also bound by the prior Federal Circuit judgment regarding claim construction? What would have happened if the reissue was asserted in a second lawsuit or against a different party? …

Statutory Interpretation and the Exhaustion Issues in Lexmark v. Impression Products

As usual, Professor John Duffy is able to cast new insight on a well-worn problem. In the context of exhaustion, he enlists noted commercial law scholar Richard Hynes and together they walk through the underlying sources of the doctrine. Their work will likely have an important impact on the Federal Circuit’s upcoming Lexmark decision. – Dennis

Guest Post by John F. Duffy and Richard M. Hynes

In Lexmark International v. Impression Products, the Federal Circuit has now ordered en banc arguments to consider overturning not just one, but two of the court’s most important precedents on patent exhaustion.  See en banc notice on Patently-O (linking to the court’s en banc order).  Before discussing those two issues, we want to pose a question:

Q: What is the legal basis for the patent exhaustion doctrine?

(A) The doctrine is based on the U.S. Constitution.

(B) The doctrine is based solely on an interpretation of the Patent Act.

(C) The doctrine is pure judge-made law, and much like any other common-law doctrine, it is based on judicial views about good policy.

(D) The doctrine is a hybrid of statutory law and judge-made law—a judicial gloss on the Patent Act created in an era when courts felt comfortable engaging in surgery on statutes to advance judicial views about good policy.

(E) None of the above.

If the answer to this question is crystal clear to you, then you need not read any further.  But we are willing to bet that most sophisticated lawyers would answer this question incorrectly, so you really should read on.

*          *          *

Let’s start with a tried and true strategy for answering multiple choice questions—eliminating implausible answers.  First, let’s get rid of answer (E) “None of the above.”  That’s got to be wrong, because the answers essentially cover all plausible bases for any legal doctrine in domestic law.  We can also eliminate answer (A).  No court or commentator has ever argued that the doctrine is constitutionally required.

That leaves three possible options—that the doctrine is (B) statutory interpretation, (C) judge-made law, or (D) some combination of those two.  Most modern lawyers and commentators would choose (C) or (D).  They would think that the exhaustion doctrine is—wholly or partially—judge-made “common law” that reflects judicial views about good policy.  Indeed, just last month, this blog published commentary asserting that the exhaustion doctrine is based on “two policies,” including a supposed policy against allowing patentees a “double recovery” on the sale of their inventions and a supposed policy against “restraints on the alienation of chattels.” Samuel F. Ernst, Of Printer Cartridges and Patent Exhaustion: The En Banc Federal Circuit is Poised to Clarify Quanta.

Professor Ernst’s blog posting is, it is fair to say, the received wisdom among modern commentators, but we think that received wisdom to be quite clearly wrong. Our view is based on three reasons, which are summarized here but set forth in greater detail in our forthcoming article Statutory Domain and the Commercial Law of Intellectual Property (http://ssrn.com/abstract=2599074) (hereinafter Statutory Domain Article).  First, in its foundational cases on both copyright and patent exhaustion, the Supreme Court repeatedly and clearly stated that it was engaged solely in statutory interpretation. For example, the Court in Bobbs-Merrill v. Straus—the foundational copyright exhaustion case—stated explicitly that the case presented “purely a question of statutory construction.” 210 U.S. 339, 350 (1908). Similarly, in Motion Picture Patents Company v. Universal Film—an important case on patent exhaustion from the same era—the Court quoted the language of the patent statute granting exclusive rights; stated that it was “interpreting this language of the statute”; and emphasized that it was trying to “determine the meaning of Congress” in writing that language. 243 U.S. 502, 509-10 (1917). Modern commentators have tended either to ignore these portions of the Supreme Court’s opinions or to assert that the Supreme Court was dissembling in those passages.  (For examples, see Statutory Domain Article, at 6 n.16.) We think the Court was telling the truth and that the exhaustion doctrine is based purely on statutory interpretation.

A second reason for doubting the received wisdom about exhaustion is that the foundational cases consistently state their holding in terms of the relevant issue being “outside,” “beyond” or “not within” patent law.  See, e.g., Motion Picture Patents, 243 U.S. at 509; Bloomer v. McQuewan, 55 U.S. 539, 549 (1852); Boston Store of Chicago v. American Graphophone Co., 246 US 8, 24 (1918). Such statements are inexplicable if patent law itself were concerned with limiting patentees’ ability to impose post-sale encumbrances on personal property.  Those statements are, however, completely consistent with the exhaustion doctrine being based on statutory interpretation, for they fit perfectly with the view that exhaustion represents an inferred limit on the “scope” or “domain” of the Patent Act.  (For a much more complete discussion of such domain limitations, see Statutory Domain Article at 24-31.) In other words, the underlying basis for the exhaustion doctrine is not substantive policies such as hostility toward restraints on alienation, but rather an absence of substantive policy on the issue within the Patent Act. Such issues are instead governed by a vast body of commercial law—including the law of contracts, security interests, personal property servitudes, antitrust, etc.—that permits all sorts of restraints on alienation, use restriction and encumbrances in some, but not all, circumstances.  The exhaustion doctrine insures that IP law does not displace that vast and complex body of law in circumstances where Congress had no intent to do so.

Third and finally, the principal cases on exhaustion also consistently state that the Court is not deciding on the enforceability of any rights that the patentee may have under non-patent law.  One classic statement is found in Keeler v. Standard Folding Bed, 157 US 659, 666 (1895), where the Court concluded its analysis: “Whether a patentee may protect himself and his assignees by special contracts brought home to the purchasers is not a question before us, and upon which we express no opinion. It is, however, obvious that such a question would arise as a question of contract, and not as one under the inherent meaning and effect of the patent laws.”

The correct answer to the question above is thus (B)—the exhaustion doctrine is pure statutory interpretation and does not reflect judicial hostility toward restraints on alienation or encumbrances generally.

This approach throws a new light on the questions that the Federal Circuit will address in its en banc decision.  One of the en banc questions is whether the court should overrule Mallinckrodt, Inc. v. Medipart, Inc., 976 F.2d 700 (Fed. Cir. 1992), and here the answer is surely “yes.”  The Supreme Court case law establishes a pretty clear bright-line rule that the exclusive rights to make and use in the Patent Act are exhausted upon the first authorized sale or other transfer of ownership.  (See Statutory Domain Article at 46-49.) Importantly, however, that bright-line rule is based on statutory considerations—Congress had no intention to displace the vast and complex law governing property encumbrances and other aspects of general commercial law.  The rule is not based on a view that the Patent Act explicitly or implicitly has any hostility towards post-sale restraints on the alienation or use of chattel property.  Patentees are therefore free to impose whatever contractual conditions they and their customers agree upon—subject, of course, to any limitations on lawful contracting imposed by state unconscionability doctrine, by federal antitrust doctrines, or by other law.

If patentees want more than mere contract rights to protect those conditions—if they want property rights that follow or “run with” the chattel—then they can encumber the chattel with a security interest.  Indeed, for nearly a century, state commercial law has treated any so-called “conditional sale” as a sale subject to a security interest. The Federal Circuit’s Mallinckrodt decision, which allowed conditional sales to be enforced through patent law without any of the nuanced limitations imposed by modern commercial law, appears to be quaintly oblivious to nearly a century’s worth of change—a throw-back to commercial law generally abandoned in this country shortly after the turn of the last century.  For the relevant history, see Statutory Domain Article at 53-54 nn. 226-30.

The other en banc question is whether the Federal Circuit should overrule Jazz Photo Corp. v. International Trade Commission, 264 F.3d 1094 (Fed. Cir. 2001), which held that U.S. patent rights are not exhausted by foreign sales. The Supreme Court’s recent decision in Kirtsaeng v. Wiley, 133 S. Ct. 1351 (2013), ruled that foreign sales do trigger copyright exhaustion, and so the Federal Circuit has quite understandably framed the issue in terms of whether foreign sales trigger patent exhaustion.  A statutory approach to the exhaustion question would, however, focus not only on the fact of a foreign sale, but also on the structure of the Patent Act’s distinct right to control importation.

In patent law, the right to control importation is a freestanding right, distinct from the exclusive right to control sales.  In copyright law, that’s not so.  A copyright owner’s exclusive right to import is defined in the statute to be part of the owner’s exclusive right to distribute under § 106(3) of the Copyright Act.  The relevant statutory language states that unauthorized importation is “an infringement of the exclusive right to distribute … under section 106.”  The statutory definition of the importation right as being within § 106(3)’s distribution rights is crucial because copyright’s codified exhaustion rule specifically points to the distribution right of §106 as the right that is to be exhausted by transfers of ownership.  See 17 U.S.C. § 109(a).

How important is this difference—that the right to import is a freestanding right in patent law but not in copyright?  Very.  The first case cited in Kirtsaeng is Quality King Distributors v. L’anza Research, 523 U.S. 135 (1998), and as Justice Kagan made clear in her Kirtsaeng concurrence, Quality King was essential to gaining a majority of the Justices.  Yet the very first step in the Court’s reasoning in Quality King was to emphasize that the Copyright Act “does not categorically prohibit the unauthorized importation [but instead] provides that such importation is an infringement of the exclusive right to distribute copies ‘under section 106.’”  From that starting point—the Copyright Act’s blending together of the right to import as part of the distribution right—Quality King was able to reason that the importation right must also be exhausted whenever the right to distribute is also exhausted, and even the copyright owner in that case could not argue that its sales did not exhaust their distribution right.

Patent law’s distinct and separate right to control importation should be controlled not by Kirtsaeng and Quality King, but by the reasoning in Buck v. Jewell-LaSalle Realty Co., 283 U.S. 191 (1931), which held that the copyright’s separate exclusive right to control public performances is generally not subject to exhaustion.  If exhaustion doctrine is a matter of statutory interpretation (as the Supreme Court has repeatedly stated), then a proper analysis of the doctrine requires attention to the specificity of rights in each statute.  The pending en banc Federal Circuit case is superficially similar as a policy matter to Kirtsaeng and Quality King (because the cases all involve international aspects of exhaustion), but in terms of statutory structure, the en banc case is more like Buck (because both cases concern a right separate from any right traditionally subject to exhaustion).

There are, of course, additional arguments on this point.  We cover many of these in our much longer article on the subject, and perhaps we will cover more in an amicus brief.  Our overarching point—and our message to other brief writers in the upcoming en banc Federal Circuit case—is that, before jumping into a policy analysis of the pro’s and con’s of various exhaustion rules, parties and amici first address whether the Federal Circuit should be engaged in pure judicial policymaking or whether, as Supreme Court precedent suggests, the court should be determining the correct interpretation of the Patent Act.

= = = = =

Read the full article here http://ssrn.com/abstract=2599074.

Federal Circuit Chooses Quantity over Quality in Fight over Electro-Mechanical Stimulation Device Patent

by Dennis Crouch

A discussion of Lelo v. USITC and Standard Innovation Corp. (Fed. Cir. 2015):

The US International Trade Commission (USITC) provides an alternate/additional forum for asserting patent rights. Unlike district court, the USITC is not empowered to award damages for past infringement but can only enjoin future importation of infringing articles through what is known as an exclusion order.  Although limited, these exclusion orders can carry substantial power – simply because so many high-tech products sold in the U.S. are manufactured abroad.

The Congressionally designated purpose of the USITC is to protect U.S. industry.  In the IP context, this purpose has been implemented as a requirement that USITC patent assertions be associated with a domestic industry.  Under Section 337(a) of the Tariff Act of 1930 (as substantially amended), “with respect to the articles protected by the patent,” the patentee must show that there is, within the U.S.:  “(A) significant investment in plant and equipment; (B) significant employment of labor or capital; or (C) substantial investment in its exploitation, including engineering, research and development, or licensing.” 19 U.S.C. § 1337(a)(3).  To be clear, although the USITC requires a domestic industry related to products covered by the patent, there is not requirement that the patentee be a U.S. company.

StandardInnovationCorpHere, the owner of the asserted U.S. patent No. 7,931,605 is the Canadian company Standard Innovation Corporation.  The invention covers an “electro-mechanical sexual stimulation device to be worn during intercourse.” The Federal Circuit euphemistically identifies this as a “kinesiotherapy device.”

Standard Innovation has its products manufactured in China, although the company does use some U.S. sourced components (such as the backbone material, rubber, pigment, and control-chip wafer). The manufactured product is then shipped worldwide, including to the U.S. where a wholly-owned U.S. subsidiary distributes the product.

The question on appeal is whether a domestic industry exists under the law.  The ALJ first deciding the case found “no,” but the Commission disagreed. On appeal, the Federal Circuit has sided with the ALJ that no domestic industry exists.

In reviewing USITC decisions, the Federal Circuit generally reviews questions of law de novo but gives substantial deference to factual conclusions (substantial evidence standard).

The court’s reasoning here is somewhat odd — that the statute requires a quantitative analysis of the amount of domestic industry that was not provided by the USITC.

Quantitative Analysis: As mentioned, the domestic industry requirement requires more than an iota of domestic industry – rather  the statute requires “signficant” or “substantial” industry.  According to the court – those heightened requirements are properly interpreted as requiring a quantitative analysis:

All of the foregoing requires a quantitative analysis in order to determine whether there is a “significant” increase or attribution by virtue of the claimant’s asserted commercial activity in the United States.

Rather than conducting a full analysis of domestic industry investment, the USITC simply found that some of the component products were “critical” aspects of the final product.  For example, “the backbone material specifically allowed for beneficial flexibility and resilience, [and] the microcontrollers enabled the devices to function as a vibrator [with multiple modes]”.

On appeal, the Federal Circuit rejected these “qualitative elements” – finding that the statute requires a quantitative analysis of the impact on domestic investment and employment.

= = = =

The USITC argued that its qualitative analysis was in parallel to that done in the prior case of Certain Male Prophylactic Devices, Inv. No. 337-TA- 546, USITC Pub. 4005 (June 21, 2007) (patent at issue).  However, the court found that it didn’t fit. That is, the prior decision was appropriately characterized as quantitative in nature.

Publishing Design Patent Applications: Time to Act

Guest Post by Gary L. Griswold.  Mr. Griswold is a Consultant residing in Hudson, WI and was formerly President and Chief Intellectual Property Counsel for 3M Innovative Properties Company. The paper reflects the views of the author. He wishes to thank Bob Armitage and Mike Kirk for their excellent contributions to the paper.

Last summer I wrote a paper[1] with this same title explaining why now is the time to commence universal publication of all design patent applications filed in the United States. Indeed, recent events have made this the perfect time to legislate such transparency.

The United States has now deposited its instrument of ratification of the Geneva Act of the Hague Agreement Concerning International Registration of Industrial Designs. The Geneva Act will enter into force, in respect to the United States, on May 13, 2015. The Final Rules were published by the USPTO on April 2, 2015. U.S. applicants will be able to file under Hague, have their Hague-filed applications published by the International Bureau of the World Intellectual Property Organization at 6 months from filing, and be eligible following such international publication for provisional rights to recover a reasonable royalty under 35 U.S.C. 154(d).

For the reasons stated in my earlier paper, all U.S. design applicants—not just Hague applicants—should have the benefits that come from this type of universal examination transparency. Transparency places design patent applicants into the driver’s seat, able to head off those that may be tempted to copy a product incorporating the published design. They can develop a filing plan which meets their circumstances and know exactly when their application will be published making provisional rights available.

Importantly, the published application will produce an immediate prior art effect retroactive to its filing date once published—for both anticipation and obviousness purposes. Thus, those who would subsequently seek to obtain patents on the same design or obvious variants would be blocked.

Armed with the knowledge from published pending patent filings, competitors will have the opportunity at an early point in their commercialization process to design away from designs covered by published claims. They can thereby avoid the potential exposure under provisional rights, as well as the potential for post issuance infringement liability for the infringer’s total profits (35 U.S.C. 289).

The public will benefit from the opportunity to provide input into the examination process. Public input during the examination phase carries with it the promise of a higher quality examination and more certain patent validity. Competitors will have the ability to provide patent examiners with prior art that might otherwise not surface or be overlooked.

This is possible because the America Invents Act (AIA) offers a brief time window after publication of an application for public submissions of prior art to patent examiners. The limited duration of this opportunity assures that the speed of examination is not negatively impacted. Public input of this type can have the collateral benefit of lessening the likelihood that a PGR or IPR will be initiated based upon missed or overlooked prior art during the patent application filing and examination process.

Publication of domestic design patent applications should occur, as it does for international design patent applications under Hague, six months after the U. S. filing. In my earlier paper, I explained the reasons that 18 month publication used for utility patent application publication is inappropriate for design applications. The short examination pendency before design applications mature into issued patents dictates that design patent applications be published at six months.

Understandably, concerns over this move to transparency have been expressed by those who have grown comfortable with the pre-Hague status quo. Adapting to any new regime requires adjustments to new opportunities and new challenges. Utility patent practitioners have blazed the trail here, having gone through a major change-in-practice drill with the America Inventor’s Protection Act (AIPA) and AIA. In the end, the transparency that early publication would provide and the benefits that it would offer to clients argue strongly for professionals to embrace this change.

An important goal of the patent system is to promptly and efficiently grant valid patents on inventions that stimulate marketplace innovation. Publishing design patent applications advances that goal.

[1] Griswold, Gary L., Publishing Design Patent Applications: Time to Act¸ Patently-O (August 24, 2014), available at https://patentlyo.com/patent/2014/08/publishing-design-applications.html and IPO L.J. (August 26, 2014), available at http://www.ipo.org/wp-content/uploads/2014/08/design_patent_gg_article.pdf

Eon v. AT&T and the role of “Pure Functional Claiming”

by Dennis Crouch

In a major 2014 decision, the Supreme Court raised the standard of definiteness under 35 U.S.C. 112(b) – now requiring that the scope of patent claims be “reasonably certain” to one of skill in the art. Nautilus v. Biosig. Historically, “reasonably certain” is a high standard and has been linked with the beyond-a-reasonable-doubt standard in criminal law. I.e., claim scope that is reasonably certain may also be seen as having its scope defined beyond a reasonable doubt.  The higher standard can also be contrasted with the prior Federal Circuit that only invalidated ambiguous claims that were both insolubly ambiguous and not amenable to construction.

Despite the dramatic potential of Nautilus, the Federal Circuit has largely muted its impact.

The one area where patent-challengers see continued success is when means-plus-function claims lack appropriate structural support in the underlying patent document.  35 U.S.C. 112(f) allows a patentee to claim a “means” for accomplishing a specified function without reciting the actual structure of the mechanism or material used to accomplish the function.  However, as a rule of construction, the statute indicates that the “means” will be construed to “cover the corresponding structure, material, or acts described in the specification and equivalents thereof.”  The impact is that, although the claim appears to broadly cover a “function” it will be construed to be much more limited.  When an applicant follows this claiming approach, but fails to specify any corresponding structure within the specification then the claim is deemed invalid as indefinite.

In Eon Corp v. AT&T (Fed. Cir. 2015), the Federal Circuit has affirmed that Eon’s asserted patent claims are invalid for failing to specify the structure associated with a purely functional claim element.

Eon’s U.S. Patent No. 5,663,757 covers a data processing station that facilitates instant purchases while watching a television program.  The patent was written back when the wort “means” was still popular among patent drafters.  Here, the district court found that eight separate “means” claims were directed to “complex” computer software such as “causing selected themes to automatically display a second menu.”  Based upon that undisturbed complexity fact-finding, the appellate court found that a structure in the form of the software algorithm should have been disclosed.  Because no software algrithms were disclosed, the software means claims failed and were properly held invalid as indefinite.

Of interest here, the Federal Circuit reasoned that the algorithm is necessary to “avoid pure functional claiming.”  Quoting Aristocrat Techs. Austl. Pty Ltd. v. Int’l Game Tech., 521 F.3d 1328 (Fed. Cir. 2008).

A general purpose computer is flexible—it can do anything it is programmed to do. Therefore, the disclosure of a general purpose computer or a microprocessor as corresponding structure for a software function does nothing to limit the scope of the claim and “avoid pure functional claiming.” Aristocrat. As such, when a patentee invokes means-plus-function claiming to recite a software function, it accedes to the reciprocal obligation of disclosing a sufficient algorithm as corresponding structure.

Although the court here highlights the doctrinal point of “pure” functional claiming — claiming function with no limiting structure — the actual facts are that the disclosed microprocessor and does provide some amount of structure.  As with abstract-idea analysis, it seems here that the question is not so black-and-white, but rather whether some magical threshold has been crossed.

The case also offers some hints to the ongoing debate over subject matter eligibility of computer implemented inventions.  In particular, the court reiterated its prior statements that a “the general purpose computer becomes a special purpose computer when loaded with the special programming.”

Biosig v. Nautilus: Indefiniteness on Remand

By Jason Rantanen

Biosig Instruments, Inc. v. Nautilus, Inc. (Fed. Cir. 2015) (on remand from the Supreme Court) [2015 WL 1883265]  Download Opinion
Panel: Newman, Schall, Wallach (author)

About a month ago, I wrote an essay entitled “Teva, Nautilus and Change without Change.”  To the extent that anyone still harbored doubts about that premise in the context of Nautilus, the Federal Circuit’s opinion on remand should dispel them.  (Caveat: As I discussed in the essay, means-plus-function claims, such as the claims in Eon that Dennis will post about shortly, are a whole different ball of wax.  To me one of the most fascinating issues in patent law right now is whether the court will expand that framework to function-claiming more broadly.  The revised Nautilus opinion leaves that door a little more open than the original opinion.)

This dispute is well-known, so I’ll just summarize the procedural posture.  The district court granted summary judgment that the claims were indefinite.  On appeal, the Federal Circuit reversed, holding the claims not indefinite.  The Supreme Court granted certiorari to address the legal standard the Federal Circuit referenced on indefiniteness: that a claim is indefinite “only when it is ‘not amenable to construction’ or ‘insolubly ambiguous.'” 715 F.3d 891, 898 (2013).  In Nautilus, the Supreme Court rejected this standard:

Those formulations can breed lower court confusion, for they lack the precision § 112, ¶ 2 demands. It cannot be sufficient that a court can ascribe some meaning to a patent’s claims; the definiteness inquiry trains on the understanding of a skilled artisan at the time of the patent application, not that of a court viewing matters post hoc. To tolerate imprecision just short of that rendering a claim “insolubly ambiguous” would diminish the definiteness requirement’s public-notice function and foster the innovation-discouraging “zone of uncertainty,” United Carbon, 317 U.S., at 236, 63 S.Ct. 165, against which this Court has warned.

Nautilus, 134 S.Ct. at 2130 (2014).  The Court did not, however, resolve the overall dispute, instead returning the appeal to the Federal Circuit.

On remand the parties disputed “whether the Supreme Court articulated a new, stricter standard or whether, in rejecting the phrases ‘insolubly ambiguous’ and ‘amenable to construction,’ the Court was primarily clarifying that a patent’s claims must inform those skilled in the art with “reasonable certainty” of what is claimed.”  Slip Op. at 7-8.  The Federal Circuit did not directly answer this question, but suggested the latter through a nautical metaphor: “The Court has accordingly modified the standard by which lower courts examine allegedly ambiguous claims; we may now steer by the bright star of ‘reasonable certainty,’ rather than the unreliable compass of ‘insoluble ambiguity.'”  Id. at 9. The implication of this metaphor, combined with the passage preceding it, is that the problem the Court perceived was not that the insolubly ambiguous standard allowed too much imprecision in patent claims; the problem was that the insolubly ambiguous standard itself was too imprecise: “The Court found too imprecise our “insolubly ambiguous” standard,” Id. at 8.  The implication that Nautilus simply clarified, rather than raised, the standard for indefiniteness is further supported by an extensively-footnoted discussion of “reasonably certainty” as a “familiar standard,” one that “In the wake of Nautilus II, judges have had not problem operating under.”  Id. at 12.  The takeaway is that Nautilus offers a more precise standard, but not one that moves the target.

With this clarification in place, the panel concluded that its prior decision was correct: Biosig’s claims inform those skilled in the art with reasonable certainty about the scope of the invention.”  Id. at 14.  The court’s revised analysis turns entirely on the intrinsic evidence (“We revisit the intrinsic evidence here to make clear that a skilled artisan would understand with reasonable certainty the scope of the invention.”)  Notably missing from this discussion is any mention of Halliburton, which the court distinguished at length in the original opinion.  To the contrary: the description of the indefiniteness standard at the beginning of the opinion expressly quotes from that case: “Moreover, when a claim limitation is defined in ‘purely functional terms,’ a determination of whether the limitation is sufficiently definite is ‘highly dependent on context (e.g., the disclosure in the specification and the knowledge of a person of ordinary skill in the relevant art area).’ Halliburton Energy Servs., Inc. v. M-I LLC, 514 F.3d 1244, 1255 (Fed. Cir. 2008).”  Function-claiming remains an area to watch.

Are Specific Information-Processing Claims Abstract Ideas?

Guest Post by Jeffrey A. Lefstin, Professor of Law at the University of California, Hastings College of Law.

The Supreme Court’s decision in Alice v. CLS Bank resolved the easy cases: claims that merely recite a mode of organizing activity coupled with a generic instruction to “do it on a computer” or “do it on the Internet.” The key question left open by Alice is whether claims to specific information-processing techniques represent ineligible abstract ideas or eligible applications. Answering that question will be critical to resolving cases like California Institute of Technology v. Hughes Communications, Inc., and McRO v. Activision, discussed in Robert Stoll’s Patently-O post last month.

The patents in Caltech were directed to a method of generating error correction codes in digital transmissions. They described a method of generating parity bits by accumulating previously generated parity bits, and a sum of randomly chosen irregular repeats of message bits. Notwithstanding that the patents claimed only information-processing steps, Judge Pfaelzer of the Central District of California ruled that the claims were patent-eligible: while the claims were directed to the abstract idea of error correction, the algorithm for generating parity bits represented an inventive application of the underlying idea.

As Judge Pfaelzer recognized, that holding might be in tension with Digitech Image Technologies v. Electronics for Imaging, where the Federal Circuit, relying on Benson and Flook, suggested that any claim merely transforming information with “mathematical algorithms” is not patent-eligible. So Caltech squarely raises the question of whether specific information-processing algorithms are patent-eligible after Alice.

More generally, the significance of Benson and Flook after Alice is a critical question for future § 101 jurisprudence: much of the difficulty faced by the lower courts and the USPTO arises from attempts to reconcile the Supreme Court’s earlier caselaw with its decisions since Bilski.

It is time to acknowledge that they cannot be reconciled, and they need not be. While the Court maintains a pretense that all its opinions are coherent with each other, the regime the Court has crafted since Bilski represents a sharp break from its earlier decisions. Courts that continue to rely on Benson and Flook have not recognized the significance of Alice’s reaffirmation of the Mayo framework for patent-eligibility. For Mayo established both a different structure and a different rationale for subject matter eligibility than the Court had employed in its prior cases.

First, Mayo provided a new structure for the § 101 inquiry: step one is to identify an abstract idea or law of nature underlying the claim, and step two asks whether the claim further recites an ‘inventive concept’ that transforms the abstract idea or law of nature into a patent-eligible application. If that was not the analytical framework employed in the Court’s earlier cases, then the analysis and holdings of those cases are not necessarily relevant after Mayo and Alice. The Court itself told us in Bilski that its earlier opinions represented nothing more than explanations of the basic exceptions for laws of nature and abstract ideas.

Second, Mayo and Alice reoriented the rationale for subject-matter exclusions. Benson and Flook were premised in large part on the exclusion of subject matter not expressly authorized by Congress, the restriction of patents to tangible processes, or the exclusion of preexisting truths that exist apart from human action. Those premises were rejected in Chakrabarty, Bilski, and Alice, respectively. Instead, Mayo and Alice grounded subject matter exclusions on the ‘building-block’ concern: that patents on fundamental principles risk foreclosing more innovation than they promote.

Given the Court’s reorientation of the doctrine, Benson and Flook’s focus on ‘algorithms’ is no longer relevant. Abstract ideas, after Bilski, Mayo, and Alice, are not characterized by intangibility or field of invention. They are characterized by ‘fundamentalness’ – the concern that patents on basic concepts will foreclose too much further development. In this framework, a specific information-processing algorithm, such as an algorithm for generating parity bits, does not qualify as an abstract idea.

Caltech defined the abstract idea as the purpose of the claim, recited at a reasonably high level of generality: error correction, in the claims at issue. Identifying the abstract idea with the purpose or effect of the claim follows from the structure of the Mayo/Alice test. Step one defines the abstraction (if any) underlying the claim, while step two asks whether the application of that abstraction contains an inventive concept. The object of step one must therefore be to separate the idea of the invention from the means of application, which will be the subject of step two.

We already differentiate between idea and means of application in the law of inventorship: courts have long distinguished between formulating a goal, effect or result – which is not a contribution to conception – and formulating the means of attaining that result – which is a contribution to conception. So the Caltech analysis merely maps that long-standing distinction onto the subject-matter inquiry under § 101.

I discuss these ideas further, and develop a framework of ‘inventive concept’ applicable to both abstract ideas and laws of nature, in a forthcoming paper available here.

Louisiana Challenge’s AstraZeneca on Antitrust Claims for Asserting Invalid Drug Patents

In March 2015, the state of Louisiana filed suit against AstraZeneca alleging antitrust violations based upon the company’s actions of using its patent rights to keep generic versions of Toprol-XL off the market in Louisiana.  AstraZeneca does have patent coverage, but the state argues that the patents are both invalid and unenforceable. Read the Original State Law Complaint filed in the Parish court of East Baton Rouge.

Now, AstraZeneca has filed a notice-of-removal of the state court lawsuit to Federal Court. The plea for removal argues that the case requires determination of a substantial question of patent law (as well as other federal questions).   Under 28 U.S.C. 1441(a), removal is allowed for “any civil action brought in a State court” so long as the Federal District Court has “original jurisdiction” over the case.  In general, this is thought of as “federal question jurisdiction.”

Since Louisiana is not alleging a federal cause of action, the courts will look to the Supreme Court’s analysis in Gunn v. Minton, 133 S.Ct. 1059 (2013) to determine whether the implicit Federal Questions are substantial enough to warrant divesting jurisdiction from the state court.  Gunn was a patent law malpractice action that required determination of a number of patent law issues (such as the experimental use exception to Section 102). In that case, however, the Supreme Court found that the the patent questions were not of sufficient importance to “the federal system as a whole.”

There are a number of ways to distinguish this case from Gunn. In particular, in Gunn the Supreme Court found it important that the outcome of the legal malpractice claim would have “no broader effects.”

[A state court decision on malpractice] will not stand as binding precedent for any future patent claim; it will not even affect the validity of Minton’s patent. Accordingly, there is no “serious federal interest in claiming the advantages thought to be inherent in a federal forum.”

Gunn (quoting Grable).

Here, the outcome of the Louisiana case could have a major impact on how courts across the country handle AstraZeneca and its patents, and how courts will consider allegations of patents improperly listed in the Orange Book.  This leads me to the tentative conclusion that the patent (and other federal) questions may well be substantial enough to allow for a Federal Question.  If so, the colorful Attorney General Buddy Caldwell may soon be face-to-face with the Federal Circuit. (Read the Notice of Removal).

New Job Postings on Patently-O Jobs

The PATENT Act of 2015

Earlier today, Senator Grassley (R-Iowa) introduced the bipartisan Protecting American Talent and Entrepreneurship Act of 2015 (PATENT) Act.  The PATENT Act is a revised version of prior proposed legislation that addresses some of the most severe criticisms of those proposals.  It’s also well situated to move forward, as it’s supported by leaders from both parties.  From the bill’s summarv (Sec. 1 is the title and table of contents; Sec. 2 are definitions; if the formatting is messed up, click the link for the original source):

SEC. 3. PLEADING AND EARLY DISCLOSURE REQUIREMENTS: Form 18 is
eliminated. Plaintiffs must identify each patent and claim allegedly infringed,
which products or processes are infringing, and describe the alleged infringement.
Allows plaintiffs to describe information in general terms if it is not accessible to
them. Clarifies that pleadings can be amended and allows for confidential
information to be filed under seal. Exempts 271(e) (Hatch-Waxman and biosimilars)
proceedings. Requires plaintiffs to make additional disclosures to the court and the
PTO about the plaintiff and the asserted patents shortly after filing.

SEC. 4. CUSTOMER STAY: Allows a case against a customer to be stayed while
the manufacturer litigates the alleged infringement, provided that the
manufacturer is involved in a lawsuit in the US involving the same issues. The
customer stay is available only to those at the end of the supply chain, who are
selling or using a technology that they acquired from a manufacturer, without
materially modifying it. Allows for a stay to be lifted where it would cause undue
prejudice or be manifestly unjust.

SEC. 5. DISCOVERY LIMITS: Requires a court to stay expensive discovery
pending resolution of preliminary motions—specifically motions to dismiss, transfer
venue, and sever accused infringers. Gives a court discretion to allow limited
discovery necessary to resolve these motions or a motion for a preliminary
injunction, or if it finds that additional discovery is necessary to preserve evidence
or otherwise prevent specific prejudice to a party. Allows parties to consent to be
excluded from discovery limitations. Exempts Section 271(e) (Hatch-Waxman and
biosimilars) cases. Clarifies that timelines for responsive pleadings provided by the
Federal Rules of Civil Procedure are not altered, and nothing prohibits a court from
ordering or local rules from requiring the exchange of contentions.

SEC. 6. JUDICIAL CONFERENCE DISCOVERY REFORMS: Requires the
Judicial Conference to develop rules or procedures to address additional issues
involving discovery in patent cases. These include to what extent each party is
entitled to “core documentary evidence” and if they should be responsible for the
costs of production, and other issues involving discovery sequence and scope. Asks
the Judicial Conference to implement case management procedures for patent
cases.

SEC. 7. FEES AND RECOVERY: Provides that reasonable attorney fees will be
awarded if a court determines the position or conduct of the non-prevailing party
(plaintiff or defendant) was not objectively reasonable, unless special circumstances
make an award unjust. The winner must show that the non-prevailing party’s
position was not objectively reasonable and the judge must make a ruling for fees to shift – this is not a presumptive fee shifting rule. Fee shifting extends to cases
where a party attempts to unilaterally withdraw from a case on the eve of a trial.
Keeps 271(e) (Hatch-Waxman and biosimilars) proceedings under current law.
Fee Recovery: Requires a plaintiff to identify interested parties in the litigation,
and provides a process for a court to recover fees where the abusive litigant is
judgement-proof. If a plaintiff cannot certify it has sufficient funds to satisfy a fee
award, it must notify interested parties, who can opt out of their interest. Permits a
court to exempt institutions of higher education and qualifying parties in the
interest of justice.

SEC. 8. PRE-SUIT NOTICE/DEMAND LETTERS: Prevents vague patent
infringement demand letters from being preludes to litigation by requiring that
certain information be included in order for the letter to be considered evidence that
subsequent infringement was “willful”. If the required information is not in the
written notice, the recipient’s time to respond to a later complaint is extended by 30
days.

SEC. 9. ABUSIVE DEMAND LETTERS: Provides that, if someone violates Section
5 of the FTC Act in connection with patent assertion and has engaged in
widespread demand letters abuse, civil penalties for FTC rule violations will attach.
The provision does not impinge on legitimate licensing activity or expand the
authority of the FTC.

SEC. 10. TRANSPARENCY: Requires patent holders to disclose to the PTO
whenever there is an assignment of interest in the patent that results in a change of
ultimate parent entity. If a patent holder fails to disclose, it will not be able to
recover increased damages of attorney fees (unless this would be manifestly unjust).

SEC. 11. IP LICENSES IN BANKRUPTCY: Makes clear that as a matter of public
policy, US courts will not recognize the action of a foreign court to unilaterally
cancel a license to a US patent or trademark if the licensor goes bankrupt. Extends
current protection of licensees of US patents in bankruptcy to trademarks.

SECTION 12. SMALL BUSINESS PROVISIONS: Directs the PTO to develop
educational resources for small businesses targeted in patent suits and to provide
support to companies named in infringement actions. Instructs PTO to create a
section on its website that will list pending patent cases, so that recipients of
demand letters and defendants in lawsuits can more easily identify ongoing
litigation that may relate to their case.

SEC. 13. STUDIES: Provides for three studies on 1) the secondary market for
patents; 2) the possibility of a pilot program for a patent small claims program: and
3) business method patent quality.

SEC. 14. TECHNICAL CORRECTIONS: Technical corrections and improvements
to the AIA.

SEC. 15. EFFECTIVE DATE: Date of enactment except as otherwise provided.

SEC 16. SEVERABILITY: Should any portion of the law be held invalid, this
provision allows the rest to stand.

The full text of the bill is available here: http://www.judiciary.senate.gov/imo/media/doc/PATENT%20Act.pdf

(Entirely unrelated but also in Sen. Grassley’s Instagram feed: a few hours later he met with my Dean and the Deans of the University of Iowa College of Engineering and Division of Continuing Education.)

S.A.W.S. Class Action Lawsuit

eVideo v. U.S.A. (Ct. Fed. Clm. 2015)

In an interesting Section 1491 class-action, eVideo has filed a class-action lawsuit against the U.S. government asking for damages based upon the harm caused by the Patent Office’s S.A.W.S. program. The Sensitive Application Warning System (S.A.W.S) is the now-defunct U.S.P.T.O. program that gave double-top-secret scrutiny to applications designated as “sensitive.”  The Agency has – up to now – refused to identify which applications fell into the program (even to the applicants themselves), although a examiners inadvertently told applicants about the designation.

The harm here alleged is all USPTO and prosecution costs in applications after they were designated under the S.A.W.S. program. Joseph Zito is the lead attorney on the case.

Docs: eVideo Complaint

Commissioner Focarino Set to Retire

Margaret (Peggy) Focarino is the Commissioner for Patents for the United States Patent & Trademark Office.  She joined the USPTO in 1977 as a patent examiner and joined the Senior Executive team in 1997 under Bruce Lehman. Throughout this time, Focarino has continued as a much admired and trusted administrator of the agency.  In many ways, her role has been that of a strong stabilizing force within an office facing a rise in political pressure on a variety of fronts.  Although the job does involve setting policies regarding patent policies, much of the work is centered around operations — running a 10,000+ member governmental organization.

This week, Focarino announced her upcoming retirement scheduled for early July 2015.  Congratulations Peggy on your commitment and service to the office!

I suspect that Director Michelle Lee will name Focarino’s successor quickly.  There is a natural chain of succession that would raise one of the deputy commissioners to the role of commissioner.  Current deputies include Deputy Commissioner for Patents Operations Andrew Faile; Deputy Commissioner for Patent Examination Policy Andrew Hirshfeld; Deputy Commissioner for Patent Quality Valencia Martin-Wallace; Deputy Commissioner for Patent Administration Bruce Kisliuk; and Deputy Commissioner for the Office of International Patent Cooperation Mark Powell.  Of these, Faile and Hirshfeld are the most likely candidates. Of course, there is no requirement that Director Lee follow this order of succession or even that she appoint a “career” patent office employee to the position.

 

Pitfalls in Trademark Prosecution

Guest Post by James Major.

In a post entitled “Trademark: Registration Void if Completed Prior to Actually Rendering Services in Commerce,” Prof. Crouch asserted that “[o]ne of the traditional benefits of trademark law is that it has fewer disastrous pitfalls for the uninformed (as compared with patent law).”[1]  This guest post respectfully disagrees with Prof. Crouch and asserts that trademark law contains administrative traps for the unwary not commonly found in patent law.

Of course, a patent prosecutor and a trademark attorney can each make substantive and procedural errors; creating an estoppel and blowing a deadline, respectively, are just two.  But, substantive and procedural errors are hardly unique to patent and trademark law.  This post argues that there is the possibility of what I will call “administrative” errors that are unique to trademark law. These administrative errors arise partly because of the ease of submitting documents to the United States Patent and Trademark Office (the “USPTO”) through the Trademark Electronic Application System (“TEAS”),[2] and partly because of the fundamentals of U.S. trademark law.

1)         The Risk of Inadvertent Factual Assertions

Imagine the following scenario: the client asks the trademark attorney to submit an application for U.S. trademark registration based on a bona fide intent to use the trademark in commerce.[3]  The trademark attorney completes the form on TEAS, signs where instructed, and submits the form.[4]  Simple as that, right?  In a way, yes.  But, there’s a problem here: in submitting the intent‑to‑use application, the trademark attorney has just asserted that he or she knows the client has a bona fide intent to use the trademark in commerce.  Does the trademark attorney have first‑hand knowledge of that?  Is there evidence of “circumstances showing the good faith” of the client?[5]  A deposition would resolve those issues nicely.  And, the opposing party in a dispute could move to disqualify the trademark attorney and his or her firm from representing the client to boot.  After all, the trademark attorney is now a fact witness.

The TEAS system has a neat way round this administrative problem: the trademark attorney can e‑mail the application to the client to sign electronically.[6]  And, the signatory will hopefully have the first‑hand knowledge necessary to make the assertion under “circumstances showing the good faith” of the client.

2)         Use of the U.S. Acceptable Identification of Goods and Services Manual Can Be Dangerous

Now imagine the trademark attorney is working on behalf of a client that performs trademark searches, and only trademark searches.  The client instructs the trademark attorney to prepare an application for U.S. service mark registration of the client’s service mark, XXXXX.  The U.S. Acceptable Identification of Goods and Services Manual helpfully gives the trademark attorney plenty of options as to what recitation of services to choose, including:

  1. “Legal services”;
  2. “Legal services, namely, trademark searching and clearance services”; and
  3. “Legal services, namely, intellectual property consulting services in the field of identification, strategy, analytics, and invention.”[7]

So, the trademark attorney chooses recitation (2), e‑mails the application to the client for signature, and ultimately submits the application.  After all, the USPTO has approved all of these recitations.  But, the USPTO states:

You must ensure that statements made in filings to the USPTO are accurate, as inaccuracies may result in the cancellation of a trademark registration.  The lack of a bona fide intention to use the mark with all goods and/or services included in an application, or the lack of use on all goods and/or services for which you claim use, could jeopardize the validity of the registration and result in its cancellation.[8]

Because the client is not using the XXXXX service mark in commerce in connection with “trademark clearance services,” the client has made an inaccurate statement that could be grounds for cancellation of any service mark registration.

This administrative error may come as a surprise to patent attorneys, who typically write as broader claims as possible.  But, in U.S. trademark registration practice, there is a danger in unwitting over‑breadth.

Neither point (1) nor point (2) is a criticism of TEAS overall, nor should either be deemed so.  In some ways, TEAS is a victim of its own success.  In making trademark filing and prosecution so straightforward, it is easy to forget that one is submitting a legal document.

3)         The Joys of Good Will

Patents have the attributes of personal property.[9]  So do trademarks, inasmuch as the owners can buy them, sell them, transfer them, securitize them, etc.[10]  So, the trademark attorney take a patent assignment form and simply replace the word “patent” with the word “trademark,” right?  Wrong again, because, by making an administrative error with the form, the trademark attorney has just separated the trademark from the good will.  Prof. McCarthy defines good will as “a business value that reflects the basic human propensity to continue doing business with a seller who has offered goods and services that the customer likes and has found adequate to fulfill his needs.”[11]  And, it’s the good will that gives the trademark value.  An assignment that transfers trademark ownership but leaves the good will behind is a naked assignment that effectively destroys the value of the trademark.[12]

The solution to this administrative problem is relatively straightforward: use a form that assigns the trademark and the associated goodwill.

4)         More Assignment Antics

Now, the trademark attorney has the correct form, and assigns the intent‑to‑use application to a third party.  But, again, there’s a problem: in most cases, the statute forbids the assignment of intent-to-use applications.[13]

Given its statutory origin, there is no easy way to circumvent this administrative problem.  But, this problem is certainly an issue in trademark due diligence.

This post describes some of the administrative traps for the unwary trademark attorney.  There are probably others, only I haven’t found them (or worse, fallen into them).  But, to say that “[o]ne of the traditional benefits of trademark law is that it has fewer disastrous pitfalls for the uninformed (as compared with patent law),” hasn’t been my experience, at least on the administrative level.

= = = = = =

[1]               Dennis Crouch, Trademark: Registration Void if Completed Prior to Actually Rendering Services in Commerce, Patently-O (Mar. 2, 2015), https://patentlyo.com/patent/2015/03/trademark-registration-rendering.html.

[2]               U.S. Patent & Trademark Office, http://www.uspto.gov/trademarks-application-process/filing-online (last visited Mar. 9, 2015).

[3]               See 15 U.S.C. § 1051(b) (2012).

[4]               See generally Trademark/Service Mark Application, Principal Register, U.S. Patent & Trademark Office, 1‑21, http://www.uspto.gov/sites/default/files/documents/new_teas.pdf (last visited Mar. 9, 2015) [hereinafter TEAS Regular Form] (providing a preview of a “TEAS Regular” form).

[5]               15 U.S.C. § 1051(b).

[6]               TEAS Regular Form, supra note 4, at 18‑19.

[7]               U.S. Patent & Trademark Office, U.S. Acceptable Identification of Goods and Services Manual (ID Manual), http://tess2.uspto.gov/netahtml/tidm.html (enter “legal services”) (last visited Mar. 9, 2015).

[8]               TEAS Regular Form, supra note 4, at 15 (underlining added).

[9]               35 U.S.C. § 261.

[10]             See 1 J. Thomas McCarthy, McCarthy on Trademarks and Unfair Competition § 2:14 (4th ed. 2014).

[11]             Id. § 2:17.

[12]             Id. § 2:15 (“Trademarks, unlike patents and copyrights, have no existence independent of the good will of the products or services in connection with which the mark is used.”).

[13]             15 U.S.C. § 1060(a)(1).

FDA Law: You’re Invited . . . To a Dance Party! Will You Dance the Amgen Waltz, or the Sandoz Shuffle?

DancePartyInvite

Guest Post By Kurt R. Karst.  Mr. Karst runs the excellent FDA Law Blog and is also a director at Hyman, Phelps & McNamara. The following was originally published on the FDA Law Blog.  

As you enter the Courtroom 402 “dance hall” at the U.S. Court of Appeals for the Federal Circuit on Wednesday, June 3, 2015, you’ll have to decide whether to take an initial right step and join the Amgen Inc. (“Amgen”) crowd, or move to the left and side with the folks from Sandoz Inc. (“Sandoz”) as the two sides battle over the applicability and correct interpretation of various provisions of the the Biologics Price Competition and Innovation Act of 2009 (“BPCIA”) in the context of Sandoz’s biosimilar version of Amgen’s NEUPOGEN (filgrastim), ZARXIO (filgrastim-sndz), which FDA licensed on March 6, 2015 under BLA 125553.  You’ll need to RSVP soon, however, because space is filling up fast!  There’s already a lineup of parties who want to be at the “must attend” BPCIA event of the year.

The party at the Federal Circuit was kicked off after Judge Richard Seeborg of the U.S. District Court for the Northern District of California ruled on March 19, 2015 in a 19-page decision that, among other things, the BPCIA’s reticulated information exchange and patent resolution procedures are not mandatory for Section 351(k) biosimilar applicants, and that the plain language of the statute allows for the 180-day notice of commercial marketing to come well before the licensure of a Section 351(k) application (see our previous post here).

The decision was a total victory for Sandoz, and thus, a total defeat for Amgen, which promptly appealed the decision to the Federal Circuit (see our previous posthere).  Meanwhile, back in District Court, Amgen filed a Motion for Injunction Pending Appeal.  But Judge Seeborg denied that motion as well, saying that Amgen’s “tenuous and highly contingent showing of irreparable harm forecloses injunctive relief.”  Undeterred, and facing a possible launch of ZARXIO as early as Monday, May 11, 2015, Amgen is now asking the Federal Circuit for an Injunction Pending Appeal.  Sandoz recently filed its Opposition to Amgen’s motion, saying that “Amgen’s appeal involves no claim of patent infringement,” and instead, “Amgen seeks to enjoin launch of Sandoz’s FDA-approved biosimilar filgrastim product based solely on Sandoz’s purported violations of procedures of the [BPCIA],” which “contains no mechanism for Amgen to preclude Sandoz from launching absent a showing of patent infringement.”

Briefing on Amgen’s appeal is nearly complete.  As we previously reported, Amgen filed its Opening Brief on April 3, 2015 laying out the company’s arguments as to why Judge Seeborg erred in ruling on all fours for Sandoz.  Not long thereafter, Amgen received support from several parties that filed amicus briefs.  (Amgen’s Reply Brief is due on April 28, 2015.)

Janssen Biotech, Inc. (“Janssen”) urges the Federal Circuit in its amicus brief to “clarify that the statutory patent dispute resolution procedures are intended to be followed as written, and are not merely optional choices or empty formalities, as Sandoz contends.”  Janssen is currently challenging, in the U.S. District Court for the District of Massachusetts, Celltrion, Inc.’s (“Celltrion’s”) and Hospira, Inc.’s (“Hospira’s”) decision to exit from the BPCIA’s patent dance procedures in the context of a biosimilar version of Janssen’s REMICADE (infliximab) (see our previous post here).

AbbVie Inc. (“AbbVie”), which markets HUMIRA (adalimumab), among many other products, has not yet had to engage in litigation over the BPCIA’s information exchange and patent resolution provisions, but weighs in for Amgen in an amicus brief.  According to AbbVie, absent a reversal of Judge Seeborg’s decision, biosimilars patent litigation will devolve into chaos:

The outcome of this appeal will have a profound effect on the transparency, efficiency, and fairness of the legal process going forward. If Amgen’s positions are adopted—and Congress’s directives are enforced—parties will enter the litigation process well informed; they will be able to identify the patents truly at issue, engage in good-faith negotiations, narrow their disputes, and litigate only those issues that warrant the courts’ time and attention.  If Sandoz were to prevail, the entire biosimilar litigation process would become a free-for-all, where biosimilar companies would utilize the data and work of innovator companies but refuse to provide basic information about their products, including their compositions, indications, formulations, and manufacturing processes, as well as the timing of their planned launches, leaving innovators to blindly guess as to which patents they should sue on and when.  The first option will lead to more focused cases, more transparency, and more frequent and earlier settlements; the second will burden the courts with inefficient and protracted litigation for years to come.

Finally, the Biotechnology Industry Organization (“BIO”), whose members include both Amgen and Sandoz, says in its amicus brief that “the BPCIA patent dispute resolution process must be interpreted in accordance with its purpose — to provide a significant and real opportunity to resolve patent issues prior to the launch of the biosimilar,” which requires, in turn, “notice to the reference product sponsor of the initial submission of the biosimilar application and notice of potential commercial marketing upon approval.”

Sandoz, in the company’s April 21, 2015 Non-Confidential Brief, does an excellent job of laying out why the waltz preferred by Amgen and its supporters is not the only move on the dance floor, and why a shuffle (or perhaps a side step?) is perfectly reasonable under the BPCIA.  According to Sandoz:

Read in the context of the BPCIA as a whole, the “shall” provision in Section 262(l)(2)(A) is a mandatory condition precedent to engaging in the patent-exchange process, not a mandatory requirement in all circumstances. . . .  This interpretation is consistent with uses of “shall” in other provisions in subsection (l), as well as with uses of “shall” in other statutory schemes.  It also gives full effect to both “shall” and “may” in subsection (l)(2)(A). . . .  Congress carefully balanced the interests between sponsors and applicants, determined what the consequences should be at each step of the process for not completing it, and allowed the parties to weigh the benefits of proceeding against the consequences of not.

With respect to notice, says Sandoz, “[t]he plain terms of the ‘[n]otice of commercial marketing’ provision are satisfied when an applicant provides notice at least 180 days before it commercially markets its product.”  “If, as Amgen argues, a biosimilar must be licensed before notice may be given, that would transform this mere ‘[n]otice’ provision into an automatic, six-month bar against marketing of every licensed biosimilar product. Had that been Congress’s intent, it would have said so.”

Sandoz’s arguments are reinforced in an amicus brief filed by the Generic Pharmaceutical Association (“GPhA”), which recently announced the launch of a new division, called the Biosimilars Council.  According to GPhA:

The question here is whether the BPCIA’s patent dispute resolution provisions should be interpreted according to the statute’s clear structure, which in turn supports Congress’s overarching goals of increased competition and consumer access to affordable biologics.  The answer, as the district court found, is yes.  The contrary readings advanced by Amgen and its amici depend on illogical, context-free interpretations of selected individual words that if read as Amgen suggests would render superfluous important sections of the BPCIA, undercut the statute’s overarching purposes, and produce results that Congress could not possibly have intended.

According to a recent docket entry, Celltrion and Hospira also tendered an amicus brief that has only just been made public and is available here.

Blocking Torrents in the UK

I enjoy teaching a variety of law related courses. Thus, in addition to our more standard IP offerings, I have also taught property law, civil procedure, licensing, etc. One of my favorite courses is Internet Law. I enjoy that class because I end up learning a tremendous amount from students as both the technology and culture of our electronic society continues to change.

In an important internet and copyright law case, the English Court has just ordered a host of internet service providers to shut-down access to a set of websites that facilitate online copyright infringement.  20th Centruy Fox v. Sky UK, 2015 EWHC 1082. (High Court of Justice for England and Wales).  The action pits media companies (who are the copyright holders) against internet service providers who provide internet access to both home and business users.  The reality, however, is that the ISPs appeared to ready to concede and comply with the court order that effectively removes this black-market access from UK consumers.  It was only Judge Birss who forced the parties to prove their case.

Section 97A of the UK Copyright, Designs, and Patents Act of 1988 provides for “injunctions against service providers” who have “has actual knowledge of another person using their service to infringe copyright.” Here, service providers includes anyone providing “any service normally provided for remuneration, at a distance, by means of electronic equipment for the processing and storage of data, and at the individual request of a recipient of a service.”

The court breaks down the statute as having for elements:

  1. that the ISPs are service providers,
  2. that the users and/or operators of the target websites infringe copyright,
  3. that users and/or the operators of the target websites use the services of the ISPs to do that, and
  4. that the ISPs have actual knowledge of this.

Here, the only real issue is whether the new model of torrent-streaming known as “Popcorn Time” was a form of infringement (2) and whether it used the ISP services to accomplish that end (3).

To operate the Popcorn Time system, a user must install a client-program on his computer (from a Popcorn-Time-Application-Source (PTAS) website) the client-program then looks to another site as a Source of Update Information (SUI) that includes indexes of available content.  The actual streaming then occurs in a peer-to-peer scenario as well as from some “host websites” that are not part of the action here.

The alleged-infringing sites here are either PTAS sites (providing the popcorn-time client application download) or SUI sites (providing an index listing of content available) or both.

No Direct Infringement: In reviewing whether these sites infringe a copyright, Justice Birss found no direct infringement under the UK exclusive rights of “communicating copyright works to the public” because none of the sites actually cause the transfer of copyrighted material. Section 20(2)(b) of the 1988 Act.

No Authorisation: The UK copyright law makes it unlawful to “authori[se] an act restricted by copyright.”  Here, Judge Birss also found no “authorisation” because there was no evidence of any direct connection between the PTAS sites and SUI sites and the host websites.

Yes Joint Tortfeasor Liability:  The final theory of infringement turned out to be a winner for the copyright holders – that of joint tortfeasance.  Under the law previously developed by Justice Kitchen, joint tortfeasor liability in copyright law can occur:

[M]ere (or even knowing) assistance or facilitation of the primary infringement is not enough. The joint tortfeasor must have so involved himself in the tort as to make it his own. This will be the case if he has induced, incited or persuaded the primary infringer to engage in the infringing act or if there is a common design or concerted action or agreement on a common action to secure the doing of the infringing act.

Quoting Sabaf v.Meneghetti, 2002 EWCA Civ 976.

Applying this doctrine to the facts at hand, Justice Birss concluded that the suppliers of the Popcorn Time applications meet the requirements for joint liability with the operators of the host websites:

The Popcorn Time application is the key means which procures and induces the user to access the host website and therefore causes the infringing communications to occur.  The suppliers of Popcorn Time plainly know and intend that to be the case.  They provide the software and provide the information to keep the indexes up to date.  I find that the suppliers of Popcorn Time have a common design with the operators of the host websites to secure the communication to the public of the claimants’ protected works, thereby infringing copyright.

In making this decision, Justice Birss also noted the importance that the software lacks significant and practical non-infringing uses.

To be clear here, the ruling is not that the ISPs are joint tortfeasors but instead that the suppliers of the Popcorn Time application and the indexing websites are joint tortfeasors with the sites that actually host and distribute the infringing content.

Home Delivery: On question (3) above – are the ISP services being used to infringe – the court also sided with the media companies – finding that the provision of internet services to users serves “an essential role in the infringements. . . . It is through the use of the ISPs’ services that the operators of the Popcorn Time websites carry out their acts.”

ALthough the services must now be blocked in the UK – I did check and “http://afdah.com/” is still available from my Columbia Missouri Starbucks office.

Read the decision here: 20th Century Fox v Sky – Popcorn Time Approved Judgment dated 280415.

= = = = =

In the U.S., we tend to look less favorably on this style of blacklisting.  However, our culture is changing as media companies increasingly control user’s internet connection.